News & Updates

Show Multimedia Only
Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
08 Jun 2024 byJairia Dela Cruz

A large percentage of patients with relapsed/refractory multiple myeloma (RRMM) respond to the bispecific antibody linvoseltamab, with deep and durable responses seen even in the high-risk subgroups, according to data from the phase I/II LINKER-MM1 trial.

Bispecific antibody delivers positive results in relapsed, refractory multiple myeloma
08 Jun 2024
High cognitive reserve may counter dementia risk
High cognitive reserve may counter dementia risk
07 Jun 2024
ART discontinuation tied to toxicity, disease progression in mCRPC patients
ART discontinuation tied to toxicity, disease progression in mCRPC patients
07 Jun 2024

Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.

ART discontinuation tied to toxicity, disease progression in mCRPC patients
07 Jun 2024